Perrigo Company plc (PRGO) Analyst Price Target Disagreement

Wall Street Price Targets and Disagreement Spread for PRGO

Covering investment banks evaluate Perrigo through consumer packaged goods and specialty healthcare lenses. The wide target price dispersion reflects differing views on consumer OTC elasticity and regulatory turnaround timelines.

Core Reasons Behind PRGO Price Target Disagreement

The divide among Wall Street analysts covering Perrigo Company plc centers on four operational and structural factors.

• Infant Formula Remediation: Bulls expect the Gateway, Wisconsin and Vermont plants to recapture private-label store contract share as remediation capital investments conclude. Bears argue retail shelf space lost during supply disruptions has permanently shifted to branded competitors like Abbott and Reckitt.
• HRA Pharma Integration and European Performance: Cautious analysts point to sluggish European consumer demand and high amortization charges from the €1.8B HRA Pharma acquisition, while optimistic analysts point to Opill (first over-the-counter daily birth control pill in the US) as a long-term commercial driver.
• Debt Servicing vs Capital Returns: Perrigo carries over $3.7B in long-term debt. Analysts who issue conservative price targets emphasize that high interest payments constrain share repurchases and earnings growth until net debt drops below 3.0x EBITDA.
• Private Label Volume Elasticity: Equity analysts disagree on whether inflation-weary consumers will trade down to store-brand OTC medications or whether national brand promotional spending will suppress Perrigo private-label volume growth.

Valuation Scenarios Used by Research Desks

Wall Street models for Perrigo combine forward P/E multiples and discounted cash flow calculations against peer consumer health benchmarks.

Key Reporting Catalysts for PRGO Investors

Target revisions for Perrigo correlate with quarterly disclosures regarding supply-chain health and balance-sheet adjustments.

• Infant Formula Plant Utilization: Quarterly updates on manufacturing output at the Eau Claire and Georgia facilities confirm whether production volumes match customer commitments.
• Gross Margin Trajectory: Tracking gross margin recovery toward historical 38-40% levels reveals whether input cost inflation has stabilized.
• Free Cash Flow Conversion: Analysts monitor quarterly cash conversion rates to verify that operating income translates into balance-sheet deleveraging rather than working-capital drag.